Moomoo AI 已提取核心信息
Senti Biosciences, Inc. (SNTI.US) reported that its Chief Medical & Development Officer, Rajangam Kanya, was granted 101,000 shares of common stock on February 1, 2024. The transaction, which was completed on the same day, was a grant with no cost associated with the acquisition. Following this transaction, Kanya directly holds a total of 101,000 shares in the company. The grant is part of the company's compensation strategy for its executives and is indicative of the company's commitment to aligning the interests of its leadership with those of its shareholders.
Senti Biosciences, Inc. (SNTI.US) reported that its Chief Medical & Development Officer, Rajangam Kanya, was granted 101,000 shares of common stock on February 1, 2024. The transaction, which was completed on the same day, was a grant with no cost associated with the acquisition. Following this transaction, Kanya directly holds a total of 101,000 shares in the company. The grant is part of the company's compensation strategy for its executives and is indicative of the company's commitment to aligning the interests of its leadership with those of its shareholders.
Senti Biosciences, Inc.（SNTI.US）报告称，其首席医疗与开发官拉詹甘·坎亚于2024年2月1日获得了10.1万股普通股。该交易于当天完成，是一笔赠款，与收购无关。在这笔交易之后，Kanya直接持有该公司总共10.1万股股份。该补助金是公司高管薪酬战略的一部分，表明公司致力于协调其领导层的利益与股东的利益。
Senti Biosciences, Inc.（SNTI.US）报告称，其首席医疗与开发官拉詹甘·坎亚于2024年2月1日获得了10.1万股普通股。该交易于当天完成，是一笔赠款，与收购无关。在这笔交易之后，Kanya直接持有该公司总共10.1万股股份。该补助金是公司高管薪酬战略的一部分，表明公司致力于协调其领导层的利益与股东的利益。
有用
没用